Combinatorial Chemistry & High Throughput Screening ( IF 1.6 ) Pub Date : 2021-08-31 , DOI: 10.2174/1386207323666200901103732 Hetao Huang 1 , Jianke Pan 2 , Yanhong Han 1 , Lingfeng Zeng 2 , Guihong Liang 2 , Weiyi Yang 2 , Jun Liu 2
Aim and Objective: To evaluate the efficacy and safety of Chinese herbal medicines for promoting blood circulation and removing blood stasis (PBCRBSM) for preventing deep venous thrombosis (DVT) after total hip arthroplasty (THA).
Materials and Methods: The databases were searched for studies comparing the preventive abilities of PBCRBSM and Western medicine, such as low molecular weight heparin (LMWH), rivaroxaban, and aspirin, as well as for randomized controlled trials on DVT after THA. Data were analyzed using RevMan 5.3 software.
Results: A total of 3254 randomized controlled trials were included, including 1630 cases in the experimental group and 1624 cases in the control group. Meta-analysis showed that compared with Western medicine, PBCRBSM reduced the incidence of DVT (OR=0.38, 95% CI [0.30, 0.48], P < 0.001); prolonged activated partial thromboplastin time (APTT) (SMD=0.44, 95% CI [0.35, 0.53], P < 0.001); reduced D-dimer (SMD=-0.75, 95% CI [-0.84,-0.65], P < 0.001), FIB (SMD=-0.61, 95% CI [-0.72, -0.50], P < 0.001), blood viscosity (P<0.01), circumference difference in lower extremities (P<0.01), venous blood flow velocity (SMD=0.97, 95% CI [0.77, 1.16], P < 0.001), and drainage volume (SMD=-1.53, 95% CI [-1.71, -1.35], P < 0.001); and reduced adverse reactions (OR = 0.32, 95% CI [0.19, 0.56], P < 0.001). There was no significant difference in prolonging prothrombin time (PT) between traditional Chinese medicine and Western medicine (SMD = 0.07, 95% CI [-0.0.01). 3, 0.16], P > 0.05.
Conclusion: PBCRBSM is an effective method for preventing DVT after THA and has fewer adverse effects.
中文翻译：
活血化瘀中药预防全髋关节置换术后深静脉血栓形成的系统评价和Meta分析
目的与目的：评价活血化瘀中药（PBCRBSM）预防全髋关节置换术（THA）术后深静脉血栓形成（DVT）的疗效和安全性。
材料和方法：检索数据库中比较低分子肝素（LMWH）、利伐沙班和阿司匹林等西药预防能力的研究，以及THA后DVT的随机对照试验。使用 RevMan 5.3 软件分析数据。
结果：共纳入随机对照试验3254项，其中实验组1630例，对照组1624例。Meta分析显示，与西药相比，PBCRBSM降低了DVT的发生率（OR=0.38, 95% CI [0.30, 0.48], P < 0.001）；延长活化部分凝血活酶时间 (APTT) (SMD=0.44, 95% CI [0.35, 0.53], P < 0.001)；D-二聚体减少（SMD=-0.75，95% CI [-0.84,-0.65]，P < 0.001），FIB（SMD=-0.61，95% CI [-0.72，-0.50]，P < 0.001），血液黏度（P<0.01）、下肢周长差（P<0.01）、静脉血流速（SMD=0.97, 95% CI [0.77, 1.16], P < 0.001）、引流量（SMD=-1.53, 95% CI [-1.71, -1.35], P < 0.001)；和减少不良反应（OR = 0.32，95% CI [0.19, 0.56]，P < 0.001）。中西药延长凝血酶原时间（PT）无显着差异（SMD = 0.07，95% CI [-0.0.01）。3, 0.16], P > 0.05。
结论：PBCRBSM是预防THA后DVT的有效方法，且不良反应少。
京公网安备 11010802027423号